Overall survival benefit of abiraterone in mHSPC is maintained for 7 years Presented ByProf. Gerhardt Attard, UCL Cancer Institute London, UK TrialPhase 3, STAMPEDE ConferenceESMO 2022 17 November, 2022 00:23
Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment TrialPhase 3, PEACE-1, STAMPEDE, ARCHES ConferenceESMO 2021 19 November, 2021 09:27
Prostate cancer: What to expect the next 12 months TrialSTAMPEDE, ENZAMET ConferenceEAU 2019 21 May, 2019 10:27
